These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 30182159)

  • 1. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
    Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
    J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
    Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
    Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
    J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
    Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
    J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
    J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
    Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
    J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
    Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
    J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
    Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
    J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.